APC: We gave background to Inside Health Policy

CALL TO ACTION: Tell FDA to deny drugmakers’ request

Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →
APC to FDA: Just say no to Lilly

This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →
California BOP sends proposed compounding regs to comment period

The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →
Checking in on the post-Chevron fallout

What’s happened in the world of federal regulation since the end of Chevron? read more →
Hi, Noom!

Welcome to our newest Bronze-level Corporate Patron, Noom! read more →
PFMs can get 2.5% credit card processing

A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →
Phoenix compounders, rise!

The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →
APC election results: directors and bylaws

See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

August 28, 2024

We gave background to Inside Health Policy

Inside Health Policy used APC for information in its piece “Uncertainty Looms Over Bulk Production Of Personalized GLP-1 Drugs.”